Lupin Introduces Topiramate Extended-Release Capsules
Lupin Limited, a global leader in the pharmaceutical industry, has officially launched its Topiramate Extended-Release Capsules in various dosages such as 25 mg, 50 mg, 100 mg, and 200 mg in the United States. This innovation follows a successful approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA).
Therapeutic Uses of Topiramate Extended-Release Capsules
These capsules are bioequivalent to the reference listed drug, Trokendi XR Extended-Release Capsules, and are designed for numerous therapeutic applications. Specifically, they serve as an initial monotherapy for individuals aged six and older who experience either partial-onset or primary generalized tonic-clonic seizures. Additionally, the capsules act as adjunctive therapy for treating partial-onset seizures, primary generalized tonic-clonic seizures, and seizures related to Lennox-Gastaut syndrome.
Moreover, patients aged twelve and older can also use Topiramate Extended-Release Capsules as a preventive treatment for migraine, broadening its usability in everyday clinical practice.
Market Impact and Sales Forecast
According to recent data, Topiramate Extended-Release Capsules are projected to generate an estimated annual revenue of USD 164 million in the U.S. market, showcasing significant financial potential within the therapeutic space.
About Lupin Limited
Lupin Limited, headquartered in Mumbai, India, stands as a formidable force in the international pharmaceutical landscape. With a presence in over 100 markets, the company excels in delivering a wide range of pharmaceutical products, including both branded and generic formulations, complex generics, biotechnology offerings, and active pharmaceutical ingredients.
The company enjoys a reputable standing in multiple therapy areas, such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, and women’s health. With a workforce exceeding 24,000 professionals and 15 state-of-the-art manufacturing facilities along with seven dedicated research centers, Lupin is devoted to enhancing patient health outcomes globally.
Commitment to Innovation
Lupin is focused on improving healthcare by evolving its subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, each contributing to the goal of advancing treatment options and enhancing patient care.
Staying Connected
For additional information about Lupin and its innovative product offerings, the company encourages interested individuals to visit its official website and corporate presence on social media.
Frequently Asked Questions
What are Topiramate Extended-Release Capsules used for?
These capsules are indicated for treating various types of seizures and preventing migraines in eligible patients.
Who can prescribe Topiramate Extended-Release Capsules?
Qualified healthcare professionals can prescribe these capsules based on patient assessment and suitability.
What is the projected market value for Topiramate?
The annual sales forecast for Topiramate Extended-Release Capsules is estimated to reach USD 164 million in the U.S.
How does Lupin contribute to healthcare?
Lupin is dedicated to improving health outcomes through innovative pharmaceutical solutions and by expanding its market reach across multiple therapy areas.
Where is Lupin headquartered?
Lupin Limited is headquartered in Mumbai, India, and operates in over 100 markets worldwide.
